PRMT5 and ovarian carcinoma: We found that the expression of PRMT5 was positive in 22 (56.4%) of the 39 ovarian cancer patients (Table S1), and it was significantly higher in ovarian cancer than normal tissues (Figure 1C and Figure S1D).